Compare Medtronic PLC (MDT) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs MakeMyTrip Ltd — how do they compare? Medtronic PLC trades at $88.21 (market cap $112.24B), while MakeMyTrip Ltd trades at $44.41 (market cap $4.09B). The key difference: Medtronic PLC is far larger — about 27.4× MakeMyTrip Ltd's market cap, and Medtronic PLC pays a 3.28% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and MakeMyTrip Ltd for 12 Days on average.
| MDT | MMYT | |
|---|---|---|
Market Cap | $112.24B | $4.09B |
Volume | 105,663,236 | 1,828,010 |
Sector | Health | Consumer Cyclical |
52-Week High | $105.35 | $94.43 |
52-Week Low | $73.75 | $36.30 |
Typical Hold Time | 63 Days | 12 Days |
Enterprise Value | $131.58B | $4.75B |
Dividend Yield | 3.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $87.80, up 2.68% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 13.93% net income margin and consistent dividend growth over 49 years. Revenue growth accelerated to $33.54B in 2025, and analyst consensus targets $97.80, implying 11% upside. Recent news highlights regulatory approvals for medical devices and a $4B MiniMed exchange offer.
MDT offers value with a 3.2% dividend yield and reasonable valuation (P/E 21.6), but faces headwinds from technical bearishness and rising debt. The stock's appeal hinges on execution of growth initiatives in cardiovascular and neuroscience segments, though competitive and macroeconomic risks persist.
MMYT trades at $44.06, up 1.5% with bearish technical signals but strong analyst support. The company reported $978M revenue and $95M net income for 2025, though earnings have been mixed with two recent misses. Valuation metrics show high P/E of 189 but solid gross margins of 73%. Technical indicators show oversold conditions with RSI at 25.31, while institutional sentiment remains positive with 72.7% buy ratings and $77 consensus target.
The stock presents a divergence between technical weakness and fundamental optimism. Upside potential exists from the 75% analyst price target premium and planned Indian listing, but risks include volatile earnings performance, rising debt-to-asset ratio projection to 79.9%, and competitive travel sector pressures. Current levels near support at $42-43 may offer entry points for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
